Compare · DMAC vs MRK
DMAC vs MRK
Side-by-side comparison of DiaMedica Therapeutics Inc. (DMAC) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMAC and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $277.18B, about 833.6x DMAC ($332.5M).
- Over the past year, DMAC is up 47.6% and MRK is up 34.7% - DMAC leads by 12.9 points.
- MRK has been more active in the news (22 items in the past 4 weeks vs 1 for DMAC).
- MRK has more recent analyst coverage (25 ratings vs 6 for DMAC).
- Company
- DiaMedica Therapeutics Inc.
- Merck & Company Inc.
- Price
- $6.17+2.32%
- $112.17+2.74%
- Market cap
- $332.5M
- $277.18B
- 1M return
- -3.82%
- -7.19%
- 1Y return
- +47.61%
- +34.72%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 22
- Recent ratings
- 6
- 25
DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest DMAC
- DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
- SEC Form DEFA14A filed by DiaMedica Therapeutics Inc.
- SEC Form DEF 14A filed by DiaMedica Therapeutics Inc.
- SEC Form 10-K filed by DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
- DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
- DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by DiaMedica Therapeutics Inc.
- DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Parsons James T. was granted 10,095 shares, increasing direct ownership by 11% to 97,949 units (SEC Form 4)
Latest MRK
- Exe V-P & Pres. MMD Chattopadhyay Sanat exercised 2,597 shares at a strike of $110.03 and covered exercise/tax liability with 1,130 shares, increasing direct ownership by 11% to 15,347 units (SEC Form 4)
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 2,518 shares at a strike of $110.03 and covered exercise/tax liability with 1,241 shares, increasing direct ownership by 0.80% to 161,537 units (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 1,377 shares at a strike of $110.03 and covered exercise/tax liability with 679 shares, increasing direct ownership by 2% to 31,716 units (SEC Form 4)
- SVP Fin. - Global Controller Smart Dalton E. Iii exercised 1,408 shares at a strike of $110.33 and covered exercise/tax liability with 483 shares, increasing direct ownership by 11% to 9,137 units (SEC Form 4)
- Executive VP & President, MRL Li Dean Y covered exercise/tax liability with 2,326 shares and exercised 4,722 shares at a strike of $110.03, increasing direct ownership by 3% to 94,431 units (SEC Form 4)
- EVP, General Counsel Zachary Jennifer exercised 2,951 shares at a strike of $110.03 and covered exercise/tax liability with 1,454 shares, increasing direct ownership by 2% to 70,897 units (SEC Form 4)
- EVP, Chief HR Officer Larson Betty D exercised 13,435 shares at a strike of $110.81 and covered exercise/tax liability with 5,858 shares, increasing direct ownership by 122% to 13,774 units (SEC Form 4)
- EVP & CFO Litchfield Caroline exercised 3,935 shares at a strike of $110.03 and covered exercise/tax liability with 1,938 shares, increasing direct ownership by 2% to 92,301 units (SEC Form 4)
- Chairman, CEO & President Davis Robert M exercised 13,300 shares at a strike of $110.03 and covered exercise/tax liability with 6,551 shares, increasing direct ownership by 2% to 450,351 units (SEC Form 4)
- EVP, Oncology & Int?l Oosthuizen Johannes Jacobus exercised 1,377 shares at a strike of $110.03 and covered exercise/tax liability with 679 shares, increasing direct ownership by 3% to 21,895 units (SEC Form 4)